foxo4-dri senolytic peptide mechanism Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment The disordered p53 transactivation domain
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine FOXO4 DRI Peptide Senolytic & Longevity Research PeptWorld Class II senolytics inhibit survival pathways elicited by senescent Download Scientific Diagram Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv
Pay in 4 interest-free payments of $6.54 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11




